[Use of strontium-89 in the analgesic treatment of cancer patients with bone metastases].
The aim of this article was to review the available literature regarding to the use of strontium-89 in the palliation of osteoblastic bone pain. The data of many researchers showed that approximately 80% of patients with pain from osteoblastic lesions resulting from prostate or breast cancer experience significant pain relief by administration of strontium-89, with only mild levels of hematotoxicity. The duration of pain relief in some cases exceeded 3-6 months. Indications for administration of strontium-89, effectiveness and duration of the treatment, side effects are reviewed in this article.
Baranauskas
Zenonas
Z
Institute of Oncology, Vilnius University, Santariskiu 1, 08660 Vilnius, Lithuania. zenobar@loc.lt
Valuckas
Konstantinas
K
Aleknavicius
Eduardas
E
Jankevicius
Feliksas
F
Burneckis
Arvydas
A
Paviloniene
Irena
I
D000328:Adult; D001859:Bone Neoplasms / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D000075202:Contraindications; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D010006:Osteoblasts; D010148:Intractable Pain / Q000209:etiology* / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011247:Pregnancy; D011471:Prostatic Neoplasms / Q000473:pathology*; D011879:Radiotherapy Dosage; D013326:Strontium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D013326:Strontium Radioisotopes